The estimated Net Worth of Jeffrey Dierks is at least $1.4 million dollars as of 15 March 2024. Mr Dierks owns over 11,979 units of Harmony Biosciences stock worth over $446,577 and over the last 4 years he sold HRMY stock worth over $340,976. In addition, he makes $613,877 as Exec. VP & Chief Commercial Officer at Harmony Biosciences.
Mr has made over 13 trades of the Harmony Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 11,979 units of HRMY stock worth $98,467 on 15 March 2024.
The largest trade he's ever made was exercising 28,971 units of Harmony Biosciences stock on 22 August 2022 worth over $695,304. On average, Mr trades about 8,373 units every 59 days since 2020. As of 15 March 2024 he still owns at least 11,979 units of Harmony Biosciences stock.
You can see the complete history of Mr Dierks stock trades at the bottom of the page.
Jeffrey Dierks M.B.A. is the Exec. VP & Chief Commercial Officer at Harmony Biosciences.
As the Exec. VP & Chief Commercial Officer of Harmony Biosciences, the total compensation of Mr A at Harmony Biosciences is $613,877. There are 2 executives at Harmony Biosciences getting paid more, with John Charles Jacobs M.B.A. having the highest compensation of $933,938.
Mr A is 49, he's been the Exec. VP & Chief Commercial Officer of Harmony Biosciences since . There are 4 older and 1 younger executives at Harmony Biosciences. The oldest executive at Harmony Biosciences Holdings, Inc. is Dr. Jeffrey M. Dayno M.D., 64, who is the Chief Medical Officer.
Over the last 4 years, insiders at Harmony Biosciences have traded over $224,163,932 worth of Harmony Biosciences stock and bought 514,681 units worth $12,537,009 . The most active insiders traders include Holdings A/S Novo, Andreas Wicki et Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of $2,907,691. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth $559,200.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Harmony Biosciences executives and other stock owners filed with the SEC include: